COVID 19 from a to z
Download as PPTX, PDF
4 likes788 views
This is a kind of seminar presentation that covers the basic information about COVID 19 including virus origin, the molecular structure of the virus. It also presents adequate information on the outbreak happened all over the world and the mathematical model for prediction of what will happen later. The other part of the presentation contains a cellular mechanism of how the virus invades our body. Finally, treatment strategies are clarified.
![Best targets for treatment..Blocking infection
Kruse RL. Therapeutic strategies in an outbreak scenario to
treat the novel coronavirus originating in Wuhan,
China [version 2; peer review: 2 approved] F1000Research 2020,
9:72 (https://doi.org/10.12688/f1000research.22211.2)](https://image.slidesharecdn.com/covid19fromatoz-200406211725/85/COVID-19-from-a-to-z-27-320.jpg)
COVID 19 from a to z
- 1. COVID19 FROM ATO Z Goran Q. Othman Cell Biologist Erbil Polytechnic University 5th April 2020
- 2. The Origin of SARS-COV2
- 3. The Origin of SARS-COV2
- 8. The growing curve of death cases since 30 days of 1st recorded
- 9. The growing curve of confirmed cases per day Note the growth rate.. From tens per day in Feb to 100k per day in April
- 10. The Math. Of Epidemic: SIR Model
- 11. The Math. Of Epidemic: SIR Model
- 12. The Math. Of Epidemic: SIR Model
- 13. The Math. Of Epidemic: SIR Model
- 14. One of the controlling strategies is
- 15. Factors to be considered in Modified SIR model for COVID 19 in any region S= Number of Susceptible individuals I= Number of Exposed individuals R= Number of recovered individuals A= Number of Asymptomatic infected individuals M= Number of Mild infected individuals H= Number of hospitalized infected individuals N= Total number of Kurdistan people 硫1= Transmission coefficient of the asymptomatic infected cases to the susceptible 硫2= Transmission coefficient of the mild infected cases to the susceptible 硫3= Transmission coefficient of the hospitalized infected cases to the susceptible -1=Mean incubation period 了-1= Mean time between symptom onset to hospitalization 1 -1= Mean of infectious period of asymptomatic infected person for survivors 2 -1= Mean of infectious period of hospitalized infected person for survivors 隆-1= Mean time for hospitalized to death 粒= Clinical outbreak rate in all the infected cases
- 18. Role of S glycoprotein and ACE2 in virus entry
- 23. Problems facing our immune system
- 25. Problems facing our immune system
- 27. Best targets for treatment..Blocking infection Kruse RL. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China [version 2; peer review: 2 approved] F1000Research 2020, 9:72 (https://doi.org/10.12688/f1000research.22211.2)
- 28. Current Treatment Options Among the potential treatments for COVID-19 that are undergoing clinical trials to assess their safety and efficacy against the disease are: remdesivir (investigational) lopinavir/ritonavir (currently authorised as an anti-HIV medicine) chloroquine and hydroxychloroquine (currently authorised at national level as treatments against malaria and certain autoimmune diseases such as rheumatoid arthritis) systemic interferons and in particular interferon beta (currently authorised to treat diseases such as multiple sclerosis) monoclonal antibodies with activity against components of the immune system Ivermectin which is used as antiparasites especially related to skin